DongBang Medical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DongBang Medical makes single-use acupuncture needles and cupping cups used in traditional Korean medicine, as well as aesthetic medical devices such as hyaluronic acid dermal fillers, cannulas, needles, and biodegradable absorbable sutures.
Its products reach hospitals, pharmaceutical companies, and distributors both domestically and across more than fifty countries spanning Asia, North America, South America, and Europe. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across two main product lines, traditional Korean medical devices and aesthetic medical devices, with the aesthetic segment, particularly dermal fillers, representing a growing share of its business.
Summary is AI-generated and may contain errors · figures from DART filings
DongBang Medical participated as the domestic manufacturer representative in drafting the international single-use sterile acupuncture needle standard, which has since been adopted as a Korean national standard.
DongBang Medical in five facts
What does DongBang Medical do?
DongBang Medical makes single-use acupuncture needles and cupping cups used in traditional Korean medicine, as well as aesthetic medical devices such as hyaluronic acid dermal fillers, cannulas, needles, and biodegradable absorbable sutures.
Where is DongBang Medical listed and in which sector?
DongBang Medical (Korean name: 동방메디컬) trades under KRX code 240550 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is DongBang Medical?
Its market capitalisation was US$89.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DongBang Medical's latest annual revenue and operating profit?
For fiscal year 2025, DongBang Medical reported revenue of US$85.7M, operating profit of US$12.8M and net income of US$8.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 8.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingSep 8
- Investor relations (IR) meetingSep 8
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DongBang Medical reported consolidated results for FY2025: revenue of US$79.5M (+7.92% year on year), operating profit of US$11.9M (+13.24% year on year) and net income of US$8.03M (+266.52% year on year).
Earnings · Feb 26